Haoding ADC platform authorizes Novartis, a major international pharmaceutical company, with a total potential transaction value exceeding US$2 billion

On the right is Liang Gengyi, Chairman of Haoding, and on the left is Acting CEO Chen Yaqi. (Photo by reporter Chen Yongji)

[Reporter Chen Yongji/Report from Taipei] Taiwan's Aldino Biotechnology (4174) held a major press conference today to announce that it has signed a cooperation and licensing agreement with the world's leading pharmaceutical company Novartis Pharma AG. Novartis will use Aldino's multiple proprietary Antibody-Drug Conjugate (ADC) platform technologies to develop next-generation ADC drugs equipped with new drug payloads.

According to the agreement, Haoding will receive a signing bonus of US$30 million (approximately NT$980 million) and the opportunity to obtain milestone payments based on subsequent research and development, regulatory approval and commercialization progress. The total potential transaction value exceeds US$2 billion. In addition, Haoding also has the right to receive profit sharing royalties based on the net sales of the authorized products generated by the cooperation between the two parties.

Haoding pointed out that according to the agreement, Novartis will obtain the global exclusive license for Haiding's related ADC platform technology, patents and professional technical knowledge for specific and undisclosed drug loads. At the same time, in this cooperation, Haoding will evaluate new linker technology combined with Novartis drug payloads. In addition, Novartis also has the option to expand the scope of cooperation to other new drug load categories in the future.

This cooperation is an important milestone in the development of Haoding. It highlights the value of Haoding's differentiated ADC technology platform and reflects the development potential of Haoding's independently developed patented technologies such as GlycOBI®, EndoSymeOBI®, HYPrOBI® and GlycOBI DUO®. It will also help Haoding expand the application of ADC technology around the world through strategic cooperation.

Shiva Malek, global head of oncology at Novartis Biomedical Research, said: "Combining Halogen's expertise in the field of antibody-drug complexes to develop potential ADC drugs carrying new drug payloads is an important part of Novartis' ADC oncology drug research and development strategy. This cooperation will help us continue to develop innovative therapies and expand more potential treatment options for patients."